cjc-1295 5mg ipamorelin 5mg dosage per day CJC 1295 Peptide Guide ipamorelin cjc 1295 no dac

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Animal studies document faster return to functional benchmarks in subjects treated with the peptide compared to untreated control groups

Human clinical evidence remains limited, and individual results cannot be guaranteed

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) naturally increases in youthful skin and declines with age

Potentiation induced by IGF-1 DES was initiated within 5 minutes of application when the treatment was administered at concentrations of 40 ng/ml